Maybe not material, but from a risk management perspective, having multiple products on the market, each contributing a little to EBITDA, then if one drug is recalled, the business impact is not as great. If CSL only had a few products in the market, the risk of the impact of a recall is much much greater.
HT1
Ann: IDELVION(R) (rFIX-FP) - European Commission Approval-CSL.AX, page-4
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$306.03 |
Change
0.290(0.09%) |
Mkt cap ! $147.7B | |||
| Open | High | Low | Value | Volume |
| $304.40 | $307.10 | $303.30 | $145.5M | 477.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 157 | $306.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $306.54 | 305 | 1 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| CSL (ASX) Chart |